Cepheid Agrees To Be Acquired By Danaher Corporation For $53 Per Share In Cash
PR Newswire September 6, 2016
SUNNYVALE, Calif., Sept. 6, 2016 /PRNewswire/ -- Cepheid (CPHD) today announced that it has entered into a definitive agreement with Danaher Corporation (DHR) under which Danaher will acquire all of the outstanding shares of Cepheid common stock for $53 per share in cash, or a total enterprise value of approximately $4 billion including indebtedness and net of acquired cash.
"Cepheid's vision has always been to enable as many people as possible to have access to powerful molecular diagnostic tests that provide critical information on a timely basis to guide treatment and patient management," said John Bishop, Cepheid's Chairman and Chief Executive Officer. "As a standalone company for the last 20 years, Cepheid has been a leading innovator in molecular diagnostics, to date installing more than 11,000 GeneXpert Systems, and delivering tens of millions of tests spanning healthcare associated infections, critical infectious disease, sexual health, and virology."
Market Data 
Markets 
AI
